StockTake: Neurizon’s lead asset shows positive results in latest study

Neurizon Therapeutics’ (ASX:NUZ) lead drug candidate has demonstrated positive results in the latest round of testing with Tessara Therapeutics.

NUZ-001 has shown it promotes healthy and viable brain tissues, potentially demonstrating its use to provide short-term treatment for further neurodegenerative diseases. 

Watch the video to hear more.

 

This video was developed in collaboration with Neurizon Therapeutics, a Stockhead advertiser at the time of publishing.

This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

Related Topics

Explore more

Explore more

Investor Guide: Health & Biotech FY2025 featuring Tim Boreham

Read The Guide